Bristol-Myers Squibb Company (BMY) Stock

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is led by CEO Christopher S. Boerner, employs 34,100 people, headquartered in Princeton, US, publicly traded since 1972.

Bristol-Myers Squibb Company (BMY) stock trades at $59.27 with a market capitalization of $121.07B. The stock is valued at a price-to-earnings (P/E) ratio of 13.85, price-to-book of 5.75, price-to-sales of 2.61. Over the past 52 weeks the stock has ranged between $42.52 and $68.64, and currently trades 13.7% below its 52-week high. It pays a dividend yielding 4.01%.

On profitability, Bristol-Myers Squibb Company generates a return on equity (ROE) of 46.75% — well above the market average, a sign of a high-quality business, return on capital employed of 20.16%, an operating margin of 26.34%, a net profit margin of 18.87%.

In its most recent fiscal year, Bristol-Myers Squibb Company reported annual revenue of $48.2B, net profit of $7.1B, revenue has compounded at 2.5% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 1.93, a current ratio of 1.26, total assets of $90.0B, $10.2B in cash and equivalents.

BMY has a beta of 0.23 (less volatile than the overall market).